Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Glumetinib Combined With Osimertinib Mesylate Versus Platinum-based Doublet Chemotherapy in Non-Small Cell Lung Cancer Patients After Resistance to EGFR-TKIs [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating Glumetinib in combination with Osimertinib Mesylate versus platinum-based chemotherapy in non-small cell lung cancer patients …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Glumetinib
• Osimertinib Mesylate (Osimertinib)

Snippet

Sponsor: Shanghai JMT-Bio Inc. | Conditions: Non-Small Cell Lung Cancer | Phase 3 | Status: RECRUITING